Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties

Hormone and Metabolic Research

Volumn 44, Issue 7, 2012, Pages 501-505

  Ojima, A ^a   Matsui, T ^a   Maeda, S ^a   Takeuchi, M ^b   Yamagishi, S ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

AGEs; cAMP; GIP; RAGE; vascular injury

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON LIKE PEPTIDE 1; HORMONE RECEPTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANTIOXIDANTS; ENDOTHELIAL CELLS; GASTRIC INHIBITORY POLYPEPTIDE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84862209599     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1312595     Document Type: Article

References (19)

1. Yamagishi S, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des: 2005; 11 2279 2299 (Pubitemid 40872698)
2. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res: 2006; 3 73 77
3. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets: 2007; 8 1138 1143 (Pubitemid 47578142)
4. Kim W, Egan J M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev: 2008; 60 470 512
5. Winzell M S, Ahrén B. G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol Rev: 2007; 116 437 448 (Pubitemid 350116941)
6. Siegel E G, Creutzfeldt W. Stimulation of insulin release in isolated rat islets by GIP in physiological concentrations and its relation to islet cyclic AMP content. Diabetologia: 1985; 28 857 861 (Pubitemid 16176057)
7. Usdin T B, Mezey E, Button D C, Brownstein M J, Bonner T I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology: 1993; 133 2861 2870 (Pubitemid 24000747)
8. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia: 2006; 49 3094 3099 (Pubitemid 44730314)
9. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem: 2006; 281 20213 20220 (Pubitemid 44065796)
10. Ottonello L, Morone M P, Dapino P, Dallegri F. Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. Br J Haematol: 1995; 91 566 570
11. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem: 2000; 275 25781 25790
12. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, Yoshida Y, Imaizumi T. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res: 2007; 39 92 97 (Pubitemid 46909866)
13. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia: 1998; 41 1435 1441 (Pubitemid 28551614)
14. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biophys Res Commun: 2010; 391 1405 1408
15. Preiss D J, Sattar N. Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? Int J Clin Pract: 2007; 6 697 701 (Pubitemid 46449832)
16. Westrick R J, Eitzman D T. Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets: 2007; 8 966 1002
17. Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia: 2011; 54 2649 2659
18. Herman G A, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter K C, Kipnes M S, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang A Q, Zeng W, Davies M J, Tanaka W, Holst J J, Deacon C F, Gottesdiener K M, Wagner J A. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab: 2006; 91 4612 4619 (Pubitemid 44833446)
19. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med: 2000; 6 114 125